Status:

RECRUITING

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Lead Sponsor:

Boston Children's Hospital

Collaborating Sponsors:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Atopic Dermatitis

Eligibility:

All Genders

6-65 years

Brief Summary

This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermati...

Detailed Description

For this study, participants ages 6-65 years, who have atopic dermatitis and don't have any of the exclusion criteria will be invited to participate in the study. There will be a 1 time visit where qu...

Eligibility Criteria

Inclusion

  • Male or female participants ≥6 to 65 yrs of age
  • Meet AD Standard Diagnostic Criteria

Exclusion

  • Enrollment in another clinical trial
  • Hypersensitivity to an agent used for the skin decolonization protocol
  • Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
  • Phototherapy for AD within 4 weeks
  • Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
  • Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days
  • Bleach baths within 7 days of the first Visit
  • Use of oral or topical antibiotics within 21 days of the beginning of the study
  • Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
  • History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
  • Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,
  • Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.
  • Febrile illness at time of visits
  • Suspected immune deficiency or family history of primary immunodeficiency

Key Trial Info

Start Date :

November 30 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 15 2027

Estimated Enrollment :

111 Patients enrolled

Trial Details

Trial ID

NCT04455906

Start Date

November 30 2020

End Date

September 15 2027

Last Update

April 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Boston Children's Hospital

Boston, Massachusetts, United States, 02115